Androgen Deprivation Therapy for Prostate Cancer Associated With Kidney Issues

The use of androgen deprivation therapy (ADT) for prostate cancer may actually increase the risk of injury to the kidneys. These results were recently published in JAMA.

Prostate cancer is stimulated to grow from the male hormone, testosterone. Androgen deprivation therapy is a commonly used treatment modality for men with advanced prostate cancer, as it reduces the amount of testosterone in a man’s body. In turn, this slows progression of the cancer.

Researchers recently sought to determine if ADT may be associated with an increase in kidney injuries through its hormonal effects. To explore this issue, a study analyzing data from the UK Clinical Practice Research Datalink linked to the Hospital Episodes Statistics database was conducted. It included 10,250 men with newly diagnosed nonmetastatic (did not spread to distant sites in the body) prostate cancer. Approximately half of the men were treated with some type of ADT, while others were treated with different therapeutic options.

Men treated with ADT had over double the risk of developing acute kidney injury (AKI) compared to those who did not receive ADT.
This equated to an increased rate of 4.43 extra people per 1000 suffering from AKI if treated with ADT.
Certain types of ADT were associated with a higher risk of AKI than others.
The researchers concluded that ADT appears to increase the risk of AKI among men with nonmetastatic prostate cancer. However, they cautioned that further studies are required to confirm these findings, and it is important for patients and healthcare providers to outweigh risks and benefits for this treatment approach.

Reference: Lapi F, Azoulay L, Niazi M, et al. Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer. JAMA. 2013;310(3):289-296. doi:10.1001/jama.2013.8638.